Specify a stock or a cryptocurrency in the search bar to get a summary
Medicure Inc
MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. Address: 2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MCUJF
Dividend Analytics MCUJF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MCUJF
Stock Valuation MCUJF
Financials MCUJF
Results | 2019 | Dynamics |